Moderna earnings analysis: questions answered and next catalysts

Moderna Inc (MRNA) reported Q3 2026 before the open on Nov 6. The result was a swing from consistent losses to a profit.

Moderna Inc (MRNA): Trading at $256.94 (+6.41%) as of Nov 6, 12:50 PM EST (Market Cap: ~$103.7B) || Q3 EPS $0.38 vs -$1.09 est || Revenue $1.31B (+29% YoY) || Net income $162M vs -$200M a year earlier

Questions answered

• Can it make money? Yes, at least for this quarter. Net income was $162M. R&D fell 27% to $583M after several late-stage studies finished.
• Is revenue stabilizing? FY2026 growth guidance rose to 15%–25%, from "up to 10%". Stronger international COVID sales and government partnership deliveries drove it. US revenue was $780M and international was $533M.
• Is the balance sheet safe? Year-end cash guidance jumped to $8.1–8.3B, from $4.7–5.2B. R&D spend guidance fell to about $2.7B, from $2.9B.
• Does the pipeline deliver? The FDA approved the flu vaccine mFlusiva in August, the first mRNA seasonal flu shot. Phase 3 data for intismeran, Moderna’s personalized melanoma vaccine, showed a 42% lower risk of recurrence or death when combined with Merck’s Keytruda. Early data for mRNA-2808 in multiple myeloma showed a ~36% response rate.

What remains open

• Valuation. The stock is up about 765% YTD. It trades far above Goldman Sachs’ $137 target (Neutral), and above Piper Sandler’s $230 target (Overweight). William Blair downgraded on valuation, and TD Cowen holds at $90. Nov 3 and Nov 4 coverage: , .
• Durability of the beat. Q3 is the seasonal peak. Consensus has Q4 EPS at -$1.73, then Q1 2027 revenue falling to about $264M and EPS at -$1.72. FY2026 EPS consensus is -$8.42, which leaves the profit looking like a one-quarter event.
• Flu launch size. The US launch will be limited this season because approval came after contracts were set.

Next catalysts

1. Q4 results (consensus as of Nov 6). Expected revenue is about $675M with an EPS loss of $1.73. This will test whether guidance holds up.
2. Combination COVID/flu shot (mCOMBRIAX). It has EU approval, and other regulatory reviews are ongoing. Goldman expects revenue from fall 2027, after the Pfizer contract expires in 2026, with full contribution in 2028.
3. Intismeran launch. Moderna and Merck anticipate a commercial launch in 2027, so regulatory filings and updates are likely before then.
4. mRNA-2808 data. The Phase 1/2 update showed no dose-limiting toxicities. Larger cohorts are the next step.
5. Out-year estimates. Consensus has FY2027 EPS at -$4.76 on $2.43B revenue, and FY2028 EPS at -$2.85 on $3.38B. Moderna Inc (MRNA) falling below $237.86, today’s intraday low, would show the post-earnings bid fading. Moderna Inc (MRNA) rising above $267.50, today’s high and the 52-week high, would signal continued momentum.

Bottom line

The quarter answered the solvency question, since cash guidance nearly doubled. It did not settle whether a roughly $104B valuation can be supported by oncology and flu launches that start in 2027. Bulls point to cost cuts and pipeline wins. Bears point to a stock that rose about 8x in a year while near-term estimates still show losses.